Prevention or treatment: The benefits of Trichomonas vaginalis vaccine  by Cudmore, Sarah L. & Garber, Gary E.
Journal of Infection and Public Health (2010) 3, 47—53
REVIEW
Prevention or treatment: The beneﬁts of
Trichomonas vaginalis vaccine
Sarah L. Cudmore, Gary E. Garber ∗
Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa,
451 Smyth Rd., Ottawa, ON, Canada K1H 8M5
Received 15 July 2009; received in revised form 20 January 2010; accepted 25 January 2010
KEYWORDS
Trichomonas vaginalis;
Trichomoniasis;
Vaccination;
STI;
HIV
Summary Trichomoniasis (infection with Trichomonas vaginalis) is the most com-
mon non-viral sexually transmitted disease (STI) in the world. Although treatment is
available, most cases occur in developing countries, where accessing healthcare is
difﬁcult and facilities are limited. Additionally, infection is often asymptomatic and
as such goes untreated, creating reservoirs of T. vaginalis that allow the disease to
spread within the community. Because of this there has been little success in con-
trolling the incidence of trichomoniasis, especially amongst the underprivileged. The
development of a vaccine against T. vaginalis could reduce the human costs (preg-
nancy complications, infertility), medical costs (repeated doctor visits, increased
susceptibility to human immunodeﬁciency virus (HIV) infection), and societal costs
(stigma of STI, cycles of untreated infection) associated with trichomoniasis.
© 2010 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
Ltd. All rights reserved.
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Trichomonas vaginalis and
trichomoniasis
Sexually transmitted infections (STI) and their
sequelae are among the top ﬁve reasons that people
in developing countries seek medical treatment.
Amongst women of child-bearing age (15—49), STI
(excluding human immunodeﬁciency virus (HIV)
infection) are second only to complications in
pregnancy and childbirth as a cause of morbidity
and mortality [1]. The World Health Organization
(WHO) estimates that there are about 340 mil-
lion cases of curable STI annually, although high
rates of asymptomatic infection and reluctance to
seek treatment for genital disease may lead to
under-reporting. Of cases of the four major cur-
able STI, approximately 3.5% (12 million) are of
syphilis, 18.2% (62 million) are of gonorrhea, 27.1%
(92 million) are of chlamydia, and 51.2% (174 mil-
lion) are of trichomoniasis [2]. This makes infection
with T. vaginalis, a parasitic protozoan that is
the causative agent of trichomoniasis, the most
common non-viral STI in the world, with the vast
majority of infections occurring in developing coun-
tries.
T. vaginalis is the only member of the family Tri-
chomonadidae known to cause disease in humans.
Infection is spread by sexual contact and is con-
ﬁned to the genital tract [3]. Trichomoniasis in
women is a disease of the reproductive years,
although in contrast to other non-viral STI where
infection is most prevalent in younger women
(ages 15—25), the highest rates of T. vaginalis
infection are usually found in older women (ages
35—40) [4,5]. This is hypothesized to be because
untreated trichomoniasis is a chronic condition.
Several studies examining T. vaginalis infection in
women have been unable to show signiﬁcant res-
olution of infection without antibiotic treatment,
and as such the duration of infection is generally
classiﬁed as indeﬁnite [6]. About 50% of women
with T. vaginalis infection will be asymptomatic,
but about one-third of these will develop symp-
toms within 6 months [3]. Symptomatic cases of
trichomoniasis generally present with pruritis, dys-
pareunia, and vaginal discharge, as well as vaginitis
and vulvitis in more severe cases [3]. Some of
the most serious complications occur if an infec-
tion is present during pregnancy. Trichomoniasis
can lead to premature rupture of the placen-
tal membranes and result in premature labour
and low birth-weight babies [3,7]. With pregnancy
and childbirth being the leading cause of death
for women globally, an infection that can further
endanger the welfare of mother and child cannot
be ignored.
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Once considered to be mainly a disease of
omen, a number of more recent reports have
tated that trichomoniasis rates among men,
specially those who are partners of infected
omen, are much higher than previously sus-
ected [8,9]. T. vaginalis infection in men is usually
symptomatic. Symptomatic infection presents as
rethritis (dysuria and discharge) similar to other
on-gonococcal infections [3]. Unlike in women,
richomoniasis in men will usually resolve without
reatment, although there is some debate as to the
uration of infection without intervention (2 weeks
o 4 months) [10].
T. vaginalis infection does not lead to long term
mmunity and re-infection can readily occur. The
igh rate of asymptomatic infection, particularly
n men, means that many people unknowingly har-
our the parasite and act as carriers, spreading the
nfection in their community.
roblems with current treatment and
revention strategies
. vaginalis infection is treated with metronidazole.
etronidazole belongs to the 5-nitroimidazole drug
amily and it and related compounds, such as tinida-
ole and seconidazole, are reported to have about
95% success rate in curing trichomoniasis [11].
he preferred treatment regimen is a one-time oral
g dose, which combines maximum patient compli-
nce with a minimum amount of the drug (Centre
or Disease Control and Prevention (CDC) guide-
ines). Metronidazole is inexpensive and generally
ell tolerated. Severe adverse reactions to stan-
ard doses are rare and usually a result of allergic
eaction to nitroimidazoles [12].
Although metronidazole is relatively cheap and
ffective, there are still signiﬁcant barriers to
educing the global burden of T. vaginalis infec-
ions. Drug resistance to metronidazole has been
eported in 2.5—9.6% of trichomoniasis cases
13,14]. In the absence of non-nitroimidazole alter-
atives to treatment, cure can only be achieved by
ncreasing dosages of metronidazole [12]. Higher
oses lead to increased and sometimes intolera-
le side effects, which may necessitate cessation
f treatment and chronic infection.
There is also a huge disparity in the diagnosis
nd treatment of STI in developed vs developing
ountries. In industrialized countries with relatively
asy access to health care, people who experi-
nce abdominal or genitourinary discomfort usually
eek medical attention quickly. Testing is available
o establish the identity of the pathogen in ques-
ion, and the appropriate antibiotic is prescribed.
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n developing countries, access to health care may
e limited and signiﬁcant travel may be required to
each the nearest medical facility. As such, many
atients are unlikely to seek out medical care for
‘‘nuisance’’ infection (as trichomoniasis has been
escribed). Additionally, it is often not technolog-
cally or economically feasible to test for speciﬁc
athogens, so patients presenting with genitouri-
ary symptoms are given antibiotics appropriate to
he most likely cause of infection. This syndromic
reatment is very cost effective if the pathogen is
orrectly diagnosed, but it is not necessarily suc-
essful in reducing the incidence of T. vaginalis
nfection because the symptoms of trichomoniasis
discomfort and discharge in women, urethritis in
en) are often similar to other bacterial or fun-
al infections and the antibiotics commonly used
o treat these infections are ineffective against T.
aginalis. One study model has shown that even
n poorer areas it would be cost effective to add
etronidazole as part of syndromic management to
atients presenting with probable STI, when com-
ared with the cost of repeated doctor visits for
ailed cure [15]. However, syndromic treatment still
ails to address the issue of asymptomatic infections
hich act as a reservoir for the parasite.
Although the partners of patients with tri-
homoniasis are often infected, high rates of
symptomatic infection mean that they do not
lways seek treatment and as such are likely to
e-infect a partner who has been treated. Partner
reatment is recommended to prevent re-infection,
ut is generally not mandated as standard of
are [16]. As such, partner treatment relies on
he willingness of a patient with trichomoniasis
o reveal their condition to their partner(s) and
he reciprocal willingness of the partner to seek
ut testing/treatment. Even in studies where the
atient is provided with a suitable dose of metron-
dazole to provide prophylaxis for their partner,
t was shown that unwillingness of the patient to
eveal their state of infection or refusal of the
artner to accept treatment meant that consistent
artner treatment may not be achieved [16].
From a public health standpoint, the issue of
artner treatment and re-infection is particularly
ifﬁcult when dealing with sex trade workers and
heir clients. Studies have shown 13—45% of female
ex workers (FSW) are infected with T. vaginalis
17]. Contrary to the general population, younger
SW are more likely to have trichomoniasis than
lder FSW, probably because they do not or can-
ot enforce consistent condom use by clients [18].
his means that not only is the risk of contracting
nd spreading T. vaginalis greater, but increases the
ikelihood of inﬂammation and pregnancy related
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omplications. With the male to female rate of
ransmission being estimated at 85—100%, FSW who
o not use condoms consistently are at very high
isk for re-infection [19]. Although the rate of trans-
ission of T. vaginalis from female to male is still
matter of debate (studies have shown anywhere
rom 4 to 80%), male clients of FSW must still be
onsidered at high risk to become infected and may
ct as carriers to other sexual partners [19]. As
etronidazole therapy will likely not provide signif-
cant protection beyond the duration of treatment,
SW and their clients can act as a community reser-
oir for T. vaginalis and other STI.
There is also often a strong social stigma asso-
iated with diagnosis and/or treatment of genital
nfection. Women in particular may not seek treat-
ent for fear of the stigma disease will cause in
heir family or community [20]. A study on impov-
rished, pregnant African women showed that,
lthough none volunteered any symptoms, targeted
uestioning revealed that 80% had lower abdomi-
al complaints of some type. Of these women, 52%
ad at least one STI [21]. General knowledge of
TI also tends to differ between the sexes, par-
icularly in developing countries where education
pportunities for women may be limited. A survey
n India showed that women had signiﬁcantly less
nderstanding of STI transmission, prevention, and
reatment than did men. The same survey showed
isinformation can be a signiﬁcant issue. Over two-
hirds of men stated their beliefs that mothers
ho did not breast feed were intentionally harm-
ng their babies, were HIV infected, or had been
nfaithful to their husbands [20]. Embarrassment,
ultural deterrents, and lack of education on STI
ransmission, prevention, and treatment mean the
iseases like trichomoniasis will not be diagnosed
nd treated appropriately, and persistent cycles of
nfection and re-infection may occur.
. vaginalis, other STI, and HIV
hile education (e.g. proper condom use) and
ggressive treatment have been shown to reduce
TI incidence in several studies, globally the num-
er of cases of these infections continues to
ncrease. A number of studies have been under-
aken in attempt to deﬁne populations at high risk
or T. vaginalis infection. Most commonly cited risk
actors include: an infected partner, low level of
ducation, drug or alcohol abuse, prostitution, a
istory of STI and/or bacterial vaginosis (BV), and
igh risk sexual practices (e.g. unprotected sex,
ultiple partners) [22,23]. These risk factors are
ften over-lapping and are common to other STI,
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so there can be a synergistic effect that increases
the overall risk of T. vaginalis infection. A lon-
gitudinal study examining the risk of acquiring a
STI (gonorrhea, chlamydia, or trichomoniasis) found
that the strongest positive predictor was the pres-
ence of an infection at baseline. Women with a
baseline T. vaginalis infection were shown to have
the greatest risk (16.5%) of developing trichomoni-
asis again over the one year study period (taking
into account possible treatment failure). However,
the presence of gonorrhea at baseline also signif-
icantly increased the risk of T. vaginalis infection
(14.8%) when compared to women who had no STI
at baseline (2.8% acquired trichomoniasis during
the study) [22]. Another study looked at rescreen-
ing for trichomoniasis one month after treatment
in HIV-negative and -positive women. Women with
HIV were over twice as likely to be culture posi-
tive for T. vaginalis at rescreening (18.3% vs 8% for
HIV-negative), and recurrence was more likely to
be attributed to re-infection (45% vs 8% for HIV-
negative) [24]. Both studies found that re-infection
also correlated strongly with unprotected sex with
a new partner or multiple partners.
Similar to other STI, infection with T. vaginalis
has been shown to increase the risk of acquiring
HIV. Studies have shown people with trichomonia-
sis have 1.5—3 times greater risk of seroconvertion
when exposed to HIV [23,25]. As T. vaginalis is
endemic in the same areas of the world as HIV
(especially sub-Saharan Africa and south and south-
east Asia, which account for 108.5 million or 62.3%
of trichomoniasis cases annually) this increased
risk suggests that T. vaginalis infection be associ-
ated with a signiﬁcant number of people becoming
infected with HIV [2]. Additionally, co-infection
with T. vaginalis and HIV has been show to increase
cervical shedding of the virus in women [26] and
lead to higher urethral loads of HIV virus and RNA
in men [8].
A number of mechanisms have been proposed to
account for the increased susceptibility of people
with trichomoniasis to HIV. Women with trichomo-
niasis often have disrupted vaginal ﬂora, as the
presence of T. vaginalis leads to a reduction or
elimination of Lactobacillus species bacteria [27].
This causes a rise in the pH of the vagina which
in turn activates pH-sensitive trichomonal proteins
[3]. The increase in pH may not only promote the
growth of T. vaginalis, but also create a more
favourable environment for HIV as well as the
bacteria associated with other STI and BV [27].
Secreted T. vaginalis proteins and cell-to-cell con-
tact dependent mechanisms can cause disruption
of the vaginal epithelium leading the to devel-
opment of punctuate mucosal hemorrhages [28].
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hese lesions enable HIV access to underlying sub-
ucosal tissue, allowing the virus to penetrate and
pread beyond the genital tract. The protozoan also
ecretes factors that degrade protease inhibitors
hich are present in the vagina and prevent HIV
rom attaching to and entering target cells [29].
T. vaginalis infection leads to a local (vagi-
al) inﬂammatory response that is characterized by
he recruitment of neutrophils (which are present
n the discharge found in symptomatic cases), as
ell as macrophages and CD4+ (helper) T cells
hich are susceptible to infection with HIV [30,31].
his inﬂammatory response also leads to the pro-
uction of TNF- which activates CD4+ T cells,
ncreasing their susceptibility to HIV infection. T.
aginalis-induced TNF- has been shown in vitro
o signiﬁcantly increase HIV replication in infected
ells [32]. As trichomoniasis not only increases
usceptibility to HIV infection, it increases viral
eplication and shedding in T. vaginalis/HIV co-
nfected individuals, effective control of this
arasitic infection could lead to a signiﬁcant reduc-
ion in the global incidence of HIV.
dvantages of a T. vaginalis vaccine
igh risk sexual behaviors such as lack of condom
se, frequent partner change, multiple partners,
nd engaging in the sex trade represent the most
ifﬁcult obstacles to overcome in controlling the
lobal burden of trichomoniasis and all STI. High risk
ndividuals are likely to be repeatedly re-infected
nd ‘‘from a public health perspective . . . part of
core group responsible for maintaining disease
n the community’’ [22]. If prevention is based
olely on treatment, these individuals will likely
cquire and spread STI even when easily acces-
ible, inexpensive health care is available. Since
richomoniasis is endemic in areas where medi-
al facilities are often few, difﬁcult to access,
nd unaffordable, simply treating those who have
ccess to a doctor or clinic is not a viable option in
ontrolling T. vaginalis.
The development of a vaccine that could provide
ong-term protection against T. vaginalis infection
ould resolve many of the issues that currently
ndermine efforts at control and reduce trichomo-
iasis rates. Education about STI and a healthy
exual lifestyle has been shown to be effec-
ive and should continue, but high-risk individuals
ould be offered vaccination to protect them-
elves and their partners. Vaccination of women
s a part of routine gynecological or pre-natal
are would not only reduce infection rates in
omen, it would prevent trichomoniasis-related
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regnancy complications and the need to treat T.
aginalis infection in pregnant women (metron-
dazole is contraindicated in the ﬁrst trimester).
stablishing a T. vaginalis vaccine as part of rou-
ine vaccination would also help reduce the social,
amilial, and community stigma associated with
aving or seeking treatment for a genital infec-
ion.
Vaccination against trichomonad species is
lready in use commercially. Tritrichomonas foe-
us is a ﬂagellate protozoan similar to T. vaginalis
hat infects cattle. Bovine trichomoniasis is usually
symptomatic in bulls (which facilitates spread of
he disease through herds) but can cause vaginal
nﬂammation and discharge in heifers [33] symp-
oms that mirror those seen in human disease. Tr.
oetus infection can cause spontaneous abortions
n pregnant heifers [33], analogous to T. vaginalis
nfection in women causing premature labour and
ow birth weight infants. Additionally, in vitro stud-
es using various cell lines have shown that T.
aginalis and Tr. foetus exhibit similar contact-
ependent (adherence) and contact-independent
secreted proteins) mechanisms of cytotoxicity.
his cytotoxicity allows the trichomonads to dis-
upt cell monolayers in vitro, and helps establish
nd maintain infection in vivo [34,35]. Vaccinating
eifers against Tr. foetus has been shown to be very
fﬁcacious in preventing infection and reducing
ortality in fetal calves which can seriously affect
he cattle industry (Trich Guard, Fort Dodge Ani-
al Health). Given the similarity between Tr. foetus
nd T. vaginalis, development of a vaccine against
uman trichomoniasis seems both achievable and
ith the potential for huge ﬁnancial, social, and
ealth impact globally.
Signiﬁcant work has already been accomplished
ndicating that it is possible to develop a vaccine to
revent human trichmoniasis. A small human trial
f 100 women with refractory trichomoniasis was
onducted in the 1960s. These women were given
ntravaginal inoculations with increasing numbers
f heat-killed T. vaginalis. The vaccine was success-
ul therapeutically (100% improvement in clinical
ymptoms was reported) and appeared to offer
ome long-term protection. However, the study was
ever repeated and this method of vaccination has
ot been pursued, probably due to the cumbrous
echnique and need for repeated doses [36].
Immune response to T. vaginalis infection is het-
rogeneous. Examination of serum samples from
nfected women have shown that antibodies were
roduced to different protein epitopes despite
nfection by the same trichomonal strain [37].
owever some immunogenic epitopes seem to be
airly well conserved across numerous strains. Aaginalis vaccine 51
15 kDa -actin protein [38], a number of heat
hock proteins [39], and a 100 kDa protein (cur-
ently uncharacterized) [37] have been shown to
e recognized by sera from a number of differ-
nt women with trichomoniasis. These common
ntigenic epitopes mean cross-isolate protection
vaccination with one trichomonal strain protecting
gainst infection with other strains) should be pos-
ible. Alternatively a sub-unit vaccine comprised of
ighly immunogenic epitopes may provide superior
rotection by eliciting a strong immune response to
onserved protein trichomonal proteins.
A mouse model of T. vaginalis infection has
hown that, as in humans, mice can be infected,
ured with metronidazole, and readily re-infected.
owever, vaccinating mice with T. vaginalis (sub-
utaneous injection of whole cells with adjuvant)
rovides protection from subsequent vaginal infec-
ion, indicating that long-term immunological
rotection is possible [40]. Vaccination of mice
eads to increased production of antibody (IgG) and
ytokines, and increased proliferation and matura-
ion of immune cells when compared to vaginally
nfected animals (unpublished data). The existence
f a reliable and relatively inexpensive animal
odel of T. vaginalis infection will aid in eluci-
ating the speciﬁc factors required to elicit the
trong, sustained, and protective immune response
equired for an effective vaccine.
Trichomoniasis is the most common non-viral STI
n the world, and it is not a ‘‘nuisance’’ but a dis-
ase that can cause serious consequences to both
ndividual and community health. A T. vaginalis
accine could provide long-term protection instead
f short-term cures, reduce medical costs, and
revent sequelae associated with pregnancy and
nfertility. Preventing T. vaginalis infection could
ave a profound effect not only in reducing the bur-
en of treating infected individuals but on reducing
lobal HIV rates, particularly since the prospect for
n HIV vaccine is presently uncertain. The challenge
ill be to encourage investment in vaccine develop-
ent where the targeted population is in resource
oor communities.
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